Trial intelligence / Profile preview

MDex versus BMDex in untreated systemic AL amyloidosis

2010-022395-31Phase 3Completed

Sponsor: European Myeloma Network
Start: Dec 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of bortezomib, melphalan and dexamethasone in light-chain amyloidosis (2 arms), sponsored by European Myeloma Network. Primary endpoint: Hematologic response after 3 cycles of therapy. Started Dec 2010; status: completed.

Drugs

bortezomibmelphalandexamethasone

Conditions

light-chain amyloidosis

Beyond the preview

Go deeper on 2010-022395-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-022395-31.